ADHEREX EXPANDS ADH-1 TRIAL

Adherex Technologies has initiated three additional sites in Canada for its Phase II clinical trial of ADH-1 (Exherin): the BC Cancer Agency -- Vancouver Center in Vancouver, British Columbia; the Cross Cancer Institute in Edmonton, Alberta; and the QEII Health Sciences Center in Halifax, Nova Scotia, bringing the total number of clinical sites for the trial to six, including the current centers in Toronto, Montreal and Ottawa.

The Phase II single-agent trial, which is ongoing at the Ottawa Regional Cancer Centre, the Princess Margaret Hospital in Toronto and the Jewish General Hospital in Montreal, is designed to evaluate the antitumor activity and tolerability of repeated doses of ADH-1 in patients whose tumors express the molecular target N-cadherin. The trial is expected to enroll up to an aggregate of 60 patients, although the trial size could be increased beyond 60 patients depending on the level of anti-tumor activity noted.